WITH AI AND
MEET BOT IMAGE
Bot Image™, Inc. is a medical imaging software company that utilizes artificial intelligence technology for magnetic resonance imaging interpretation.
Its first product, ProstatID™ is a computer-aided diagnosis (CADx) software device used to assist radiologists in the assessment and characterization of prostate abnormalitie using MR image data. The software automatically registers images, then segments and analyzes the central gland and entire prostate organ. It identifies suspicious abnormalities by employing a pixel-wise random forest learning-based method based upon various features referenced to ground truth data on which it was trained.
ProstatID was FDA cleared for marketing on July 8, 2022.
Bot Image’s software interprets multi-parametric and bi-parametric MRI using random forest with instance weight and MR segmentation by deep learning with holistically-nested networks. ProstatID™ was trained from thousands of proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and first-pass AI interpretations to aid in the early diagnosis of prostate cancer.
Bot Image, Inc will bring early detection of prostate cancer using MRI and AI to the forefront of medicine. Our highly advanced, non-invasive technology shows promise of delivering high 90th percentile sensitivity in detection, as well as, specificity (accuracy) with the near elimination of false positives and false negatives. Once refined, we will then utilize the same baseline AI algorithms to address the early diagnosis of other cancers and COPD.